Genentech Catching Up In Melanoma With Cotellic Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Cotellic/Zelboraf combination, but the company already is testing the addition of a PD-L1 inhibitor.
You may also be interested in...
New Melanoma Frontier Opens To Bristol's Opdivo And Novartis/Glaxo's BRAF/MEK Combo
Bristol's Opdivo and Novartis/GlaxoSmithKline's Tafinlar/Mekinist combo both performed well in early, post-surgical treatment of advanced melanoma in trials reported at ESMO, promising yet another revolution in the standard of care, but leaving Roche's Zelboraf/Cotellic in the dust.
Melanoma Approvals Break New Ground In Immunotherapy
First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.
PD-1 Progress May Shorten The Life Of Other Drugs
With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?